Completed Enrollment

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (QWINT-5)

I8H-MC-BDCY -

The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
Insulin degludec, Insulin Efsitora Alfa, LY3209590
Could I receive a Placebo?
No
Enrollment Goal
692
Trial Dates
Aug 12, 2022 - May 2024
How long will I be in the trial?
The study will lasts about 31 visits and up to 60 weeks
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have type 1 diabetes for at least 1 year

  • Be treated with long acting and mealtime insulins allowed for study participation

  • Have blood sugar levels within allowed limits for study participation

Participants Must Not:

  • Have type 2 diabetes

  • Have had more than 1 emergency treatment or hospitalization for very low blood sugar or very high blood sugar level in the past 6 months

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources